Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression

J Leukoc Biol. 2017 May;101(5):1263-1271. doi: 10.1189/jlb.5A0816-346R. Epub 2017 Feb 13.

Abstract

Recently, alterations of the T cell expression of the ectonucleotidases, CD39 and CD73, during HIV infection have been described. Here, peripheral (n = 70) and lymph nodal B cells (n = 10) of patients with HIV at different stages of disease as well as uninfected individuals were analyzed via multicolor flow cytometry with regard to expression of CD39 and CD73 and differentiation, proliferation, and exhaustion status. Patients with chronic, untreated HIV showed a significantly decreased frequency of CD73-expressing B cells (P < 0.001) compared with healthy controls. Decreased frequencies of CD39+CD73+ B cells in patients with HIV correlated with low CD4+ counts (P < 0.0256) as well as increased proliferation and exhaustion status as determined by Ki-67 and programmed death-1 expression. Down-regulation of CD73 was observed in naive and memory B cells as determined by CD27 and CD21. Neither HIV elite controller patients nor antiretroviral therapy-treated patients had significantly lower CD39 and CD73 expression on B cells compared with healthy controls. Of importance, low CD73+ expression on B cells was associated with modulated in vitro B cell function. Further in vivo studies are warranted to evaluate the in vivo role of phenotypic loss of CD73 in B cell dysregulation in HIV.

Keywords: 5′-ectonucleotidase; ADO; CD39; Ig class switch; elite controller.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5'-Nucleotidase / genetics
  • 5'-Nucleotidase / immunology*
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-HIV Agents / therapeutic use
  • Antigens, CD / genetics
  • Antigens, CD / immunology
  • Apyrase / genetics
  • Apyrase / immunology
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / pathology
  • B-Lymphocytes / virology
  • CD4 Lymphocyte Count
  • Case-Control Studies
  • Cell Differentiation
  • Cell Proliferation
  • Disease Progression
  • Female
  • GPI-Linked Proteins / genetics
  • GPI-Linked Proteins / immunology
  • Gene Expression Regulation / immunology*
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Infections / pathology
  • HIV Infections / virology
  • Humans
  • Immunologic Memory
  • Ki-67 Antigen / genetics
  • Ki-67 Antigen / immunology
  • Lymph Nodes / drug effects
  • Lymph Nodes / immunology
  • Lymph Nodes / pathology
  • Lymph Nodes / virology
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Programmed Cell Death 1 Receptor / genetics
  • Programmed Cell Death 1 Receptor / immunology
  • Receptors, Complement 3d / genetics
  • Receptors, Complement 3d / immunology
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / genetics
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / immunology
  • Viremia / drug therapy
  • Viremia / immunology*
  • Viremia / pathology
  • Viremia / virology

Substances

  • Anti-HIV Agents
  • Antigens, CD
  • GPI-Linked Proteins
  • Ki-67 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, Complement 3d
  • Tumor Necrosis Factor Receptor Superfamily, Member 7
  • 5'-Nucleotidase
  • NT5E protein, human
  • Apyrase
  • CD39 antigen